Summary
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.
History
Bioasis Technologies Inc. was founded in 2006 by Dr. Brad Bleakney, one of the world’s leading experts in the use of specialized delivery systems for the treatment of neurological diseases and disorders. Bioasis’s cutting-edge research and technology utilizes a novel transport system to bring life-saving drugs to locations of action in a targeted manner
Mission
Bioasis’s mission is to improve the lives of patients afflicted by serious CNS disorders and to develop safe, efficient, and targeted delivery systems for the passage of therapeutics to the brain and leverage pre-existing interstitial pressure gradients of the blood-brain barrier (BBB)
Vision
Bioasis envisions a future in which transportation systems enable safe and efficient passage of therapeutics from the periphery of the body, through the BBB, to the site of action in the brain, thereby allowing for the treatment of difficult brain diseases
Key Team
Mr. Kim Elton (Director of Marketing)
Mr. Doug Williams MBA (Exec. VP & Chief Bus. Officer)
Dr. Mei Mei Tian (VP & Head of External Research)
Recognition and Awards
Bioasis has received multiple awards, including the International BIOtech Award for Most Promising Company in 2011, and the National Instruments’ Engineering Impact Award for Healthcare in 2013.
References
